Literature DB >> 26721774

Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure.

Ibrahim N Mansour1, Adam P Bress2, Vicki Groo3, Sahar Ismail1, Grace Wu1, Shitalben R Patel2, Julio D Duarte2, Rick A Kittles1, Thomas D Stamos1, Larisa H Cavallari4.   

Abstract

BACKGROUND: Procollagen type III N-terminal peptide (PIIINP) is a biomarker of cardiac fibrosis that is associated with heart failure prognosis in whites. Its prognostic significance in African Americans is unknown. We sought to determine whether PIIINP is associated with outcomes in African Americans with heart failure. METHODS AND
RESULTS: Blood was collected from 138 African Americans with heart failure for determining PIIINP and genetic ancestry, and patients were followed prospectively for death or hospitalization for heart failure. PIIINP was inversely correlated with West African ancestry (R(2) = 0.061; P = .010). PIIINP > 4.88 ng/mL was associated with all-cause mortality on univariate (hazard ratio [HR] 4.9, 95% confidence interval [CI] 2.2-11.0; P < .001) and multivariate (HR 5.8; 95% CI 1.9-17.3; P = .002) analyses over a median follow-up period of 3 years. We also observed an increased risk for the combined outcome of all-cause mortality or hospitalization for heart failure with PIIINP > 4.88 ng/mL on univariate (HR 2.6, 95% CI 1.6-5.0; P < .001) and multivariate (HR 2.4, 95% CI 1.2-4.7; P = .016) analyses.
CONCLUSIONS: High circulating PIIINP is associated with poor outcomes in African Americans with chronic heart failure, suggesting that PIIINP may be useful in identifying African Americans who may benefit from additional therapy to combat fibrosis as a means of improving prognosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African American; Heart failure; fibrosis

Mesh:

Substances:

Year:  2015        PMID: 26721774      PMCID: PMC4917490          DOI: 10.1016/j.cardfail.2015.12.016

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  52 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

3.  Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.

Authors:  Daniel Falush; Matthew Stephens; Jonathan K Pritchard
Journal:  Genetics       Date:  2003-08       Impact factor: 4.562

4.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

5.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

6.  Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000.

Authors:  David W Brown; Gail A Haldeman; Janet B Croft; Wayne H Giles; George A Mensah
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

7.  Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.

Authors:  Masayuki Kobayashi; Noboru Machida; Megumi Mitsuishi; Yoshihisa Yamane
Journal:  Am J Hypertens       Date:  2004-12       Impact factor: 2.689

8.  Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis.

Authors:  Hossein Bahrami; Richard Kronmal; David A Bluemke; Jean Olson; Steven Shea; Kiang Liu; Gregory L Burke; João A C Lima
Journal:  Arch Intern Med       Date:  2008-10-27

Review 9.  Heart failure in the ethnic minorities.

Authors:  Gordon W Moe; Jack Tu
Journal:  Curr Opin Cardiol       Date:  2010-03       Impact factor: 2.161

10.  Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.

Authors:  Hiroyuki Tsutsui; Shouji Matsushima; Shintaro Kinugawa; Tomomi Ide; Naoki Inoue; Yukihiro Ohta; Takashi Yokota; Sanae Hamaguchi; Kenji Sunagawa
Journal:  Hypertens Res       Date:  2007-05       Impact factor: 3.872

View more
  5 in total

1.  Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects.

Authors:  Nasim Vahabi; Caitrin W McDonough; Ankit A Desai; Larisa H Cavallari; Julio D Duarte; George Michailidis
Journal:  Front Genet       Date:  2021-08-02       Impact factor: 4.772

2.  NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

Authors:  Leanne Dumeny; Orly Vardeny; Frank Edelmann; Burkert Pieske; Julio D Duarte; Larisa H Cavallari
Journal:  Pharmacotherapy       Date:  2021-10-12       Impact factor: 4.705

3.  Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.

Authors:  Christelle Lteif; Meghan J Arwood; Mayank Kansal; Larisa H Cavallari; Ankit A Desai; Julio D Duarte
Journal:  J Cardiovasc Pharmacol       Date:  2020-03       Impact factor: 3.271

4.  The association between microRNA-21 and hypertension-induced cardiac remodeling.

Authors:  Ken Watanabe; Taro Narumi; Tetsu Watanabe; Yoichiro Otaki; Tetsuya Takahashi; Tomonori Aono; Jun Goto; Taku Toshima; Takayuki Sugai; Masahiro Wanezaki; Daisuke Kutsuzawa; Shigehiko Kato; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Masafumi Watanabe
Journal:  PLoS One       Date:  2020-02-10       Impact factor: 3.240

5.  Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.

Authors:  Yiling Yao; Li Feng; Yanxiang Sun; Shifei Wang; Jie Sun; Bing Hu
Journal:  BMC Cardiovasc Disord       Date:  2021-05-28       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.